<SEC-DOCUMENT>0001062993-20-004889.txt : 20201013
<SEC-HEADER>0001062993-20-004889.hdr.sgml : 20201013
<ACCEPTANCE-DATETIME>20201013101545
ACCESSION NUMBER:		0001062993-20-004889
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201013
FILED AS OF DATE:		20201013
DATE AS OF CHANGE:		20201013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	CRUDE PETROLEUM & NATURAL GAS [1311]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30314
		FILM NUMBER:		201235086

	BUSINESS ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
<head>
    <title>Portage Biotech Inc.: Form 6-K - Filed by newsfilecorp.com</title>
</head>
<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="margin-bottom: 0pt; text-align: center;"><b><font size="5">UNITED STATES</font></b></p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b><font size="5">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
    <p style="margin-top: 0pt; text-align: center;">Washington, D.C. 20549</p>
    <p style="text-align: center;"><b><font size="5">FORM 6-K</font></b></p>
    <p style="text-align: center;"><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="text-align: center;">For the month of <b>October 2020</b></p>
    <p style="text-align: center;">Commission File Number: <b>000-30314</b></p>
    <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 78%; vertical-align: middle;">
                <p style="text-align: center;"><b><u><font size="5">PORTAGE BIOTECH INC.</font></u></b></p>
            </td>
        </tr>
        <tr>
            <td style="width: 78%; vertical-align: middle;">
                <p style="text-align: center;">(Translation of registrant's name into English)</p>
            </td>
        </tr>
    </table>
    <br>
    <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 78%; vertical-align: middle;">
                <p style="margin-bottom: 0pt; text-align: center;"><b>6 Adelaide St. East, Suite 300</b></p>
                <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b><u>Toronto, Ontario, Canada M5C 1H6</u></b></p>
            </td>
        </tr>
        <tr>
            <td style="width: 78%; vertical-align: middle;">
                <p style="text-align: center;">(Address of principal executive office)</p>
            </td>
        </tr>
    </table>
    <p>Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F</p>
    <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 50%; vertical-align: middle; text-align: center;">
                <p style="text-align: center;">Form 20-F &#9746;</p>
            </td>
            <td style="width: 50%; vertical-align: middle; text-align: center;">
                <p style="text-align: center;">Form 40-F &#9744;</p>
            </td>
        </tr>
    </table>
    <p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</p>
    <p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</p>
    <p>Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</p>
    <table style="width: 100%; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 50%; vertical-align: middle; text-align: center;">
                <p style="text-align: center;">Yes &#9744;</p>
            </td>
            <td style="width: 50%; vertical-align: middle; text-align: center;">
                <p style="text-align: center;">No &#9746;</p>
            </td>
        </tr>
    </table>
    <p>If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):____________</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-align: center;"><b>SUBMITTED HEREWITH</b></p>
	<table cellpadding="0" cellspacing="0" border="0" width="100%" style="font-size:10pt;">
<tr><td width="8%" style="border-bottom:1px solid #000000;"><b>Exhibit</b></td><td width="5%">&nbsp;</td><td style="border-bottom:1px solid #000000;"><b>Description</b></td></tr>
<tr><td>&nbsp;</td><td>&nbsp;</td></tr>
<tr bgcolor="#eeeeee">
<td><a href="exhibit99-1.htm">99.1</a></td>
<td>&nbsp;</td>
<td><a href="exhibit99-1.htm">News Release dated October 13, 2020</a></td>
</tr>
</table>

    <br>
    <div id="footer_page_2">
        <p style="text-align: center;">- 2 -</p>
    </div>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: center;"><b>SIGNATURE</b></p>
    <p style="text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
    <table style="border-color: black; font-size: 10pt; border-collapse: collapse;" width="100%" border="0" cellspacing="0" cellpadding="0">
        <tr valign="top">
            <td align="left">&#160;</td>
            <td colspan="2" align="left"><b>Portage Biotech Inc.<br></b>(Registrant)</td>
        </tr>
        <tr valign="top">
            <td align="left">&#160;</td>
            <td align="left" width="5%">&#160;</td>
            <td align="left" width="45%">&#160;</td>
        </tr>
        <tr valign="top">
            <td align="left">Date: October 13, 2020</td>
            <td align="left" width="5%">By</td>
            <td style="border-bottom: #000000 1px solid;" align="left" width="45%"><i>/s/ Ian Walters</i></td>
        </tr>
        <tr valign="top">
            <td align="left">&#160;</td>
            <td align="left" width="5%">&#160;</td>
            <td align="left" width="45%">Ian Walters MD</td>
        </tr>
        <tr valign="top">
            <td align="left">&#160;</td>
            <td align="left" width="5%">&#160;</td>
            <td align="left" width="45%">Chief Executive Officer</td>
        </tr>
    </table><br>
    <div id="footer_page_3">
        <p style="text-align: center;">- 3 -</p>
    </div>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>

<head>
    <title>Portage BioTech Inc.: Exhibit 99.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade">
    <div>&#160;</div>
    <p style="text-align: center;"><img src="exhibit99-1x001.jpg" style="width: 132px;" height="57"></p>
    <p style="text-align: center;"><b>PORTAGE BIOTECH INC.</b></p>
    <p style="text-align: center;"><b>NEWS RELEASE</b></p>
    <p style="text-align: justify;">October 13, 2020</p>
    <p style="text-align: center;"><b>PORTAGE ISSUES COMMON SHARES AND WARRANTS IN SETTLEMENT OF SALVARX LOAN NOTE OBLIGATIONS</b></p>
    <p style="text-align: justify;"><b>Toronto, ON</b> - (October 13, 2020) - Portage Biotech Inc. (CSE: PBT.U, OTC Markets: PTGEF) ("Portage" or the "Company") wishes to announce that it has issued 375,014 common shares at a deemed price of US$6.64 per common share and 72,291 common share purchase warrants exercisable at a price of $6.64 per common share for a period of 2 years (collectively, the "Settlement Securities") to settle approximately US$4.4 million of certain debt obligations and equity entitlements (the "Loan Notes") of the Company's wholly-owned subsidiary, SalvaRx Limited ("SalvaRx").</p>
    <p style="text-align: justify;">The Loan Notes were originally issued in 2017. At that time, SalvaRx was a subsidiary of SalvaRx Group plc, a publicly listed company on the AIM board of the London Stock Exchange. Under the terms of the Loan Notes, upon the occurrence of a qualifying event, Loan Note holders would have been entitled to receive share purchase warrants of SalvaRx in addition to repayment of their Loan Note. The acquisition of SalvaRx by the Company in 2019 constituted a qualifying event.</p>
    <p style="text-align: justify;">The Company has settled the Loan Note obligations of SalvaRx through the issuance of the Settlement Securities. Four of the Company's directors, Gregory Bailey, James Mellon, Steven Mintz (in trust) and Kam Shah have received an aggregate of 363,718 common shares as they had all originally subscribed for Loan Notes in 2017 in an aggregate principal amount of approximately US$4.0 million. The issuance of the common shares to these directors is considered a related party transaction within the meaning of Multilateral Instrument 61-101 <i>Protection of Minority Security Holders in Special Transactions</i> ("MI 61-101"). The Company is relying on appropriate exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 in respect of these issuances.</p>
    <p style="text-align: justify;">Dr. Ian Walters, CEO of Portage, commented, "As a result of this transaction, the Company's capital structure is simpler and effectively debt free, providing significant financial flexibility to further fund and expand development of innovative drugs to help cancer patients."</p>
    <p style="margin-bottom: 0pt; text-align: justify;">All Common Shares issued in connection with the Offering are subject to a minimum statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Common Shares issued in connection with the Offering have not been registered under the U.S. Securities Act of 1933, as amended (the "Act"), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available.</p>
    <hr style="page-break-after: always;" width="100%" size="5" color="black" noshade="noshade">
    <p style="margin-top: 0pt; text-align: center;">-2-</p>
    <p style="margin-top: 0pt; text-align: justify;"><b>About Portage Biotech Inc.</b></p>
    <p style="text-align: justify;">Portage Biotech is a clinical stage biopharmaceutical company developing an innovative&#160; portfolio of immuno-oncology assets. Our oncology focussed products or technologies are based on biology addressing known resistance pathways/mechanisms of current check point inhibitors with established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. We create and execute viable cost-effective product development strategies by delivering superior clinical trial design, and project management, to ultimately build value and support commercial potential in, first- and best-in-class therapies for a variety of cancers.&#160;</p>
    <p style="text-align: justify;"><i><b>Forward-Looking Statements</b></i></p>
    <p style="text-align: justify;">This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties.&#160; Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.</p>
    <p style="text-align: justify;">Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.</p>
    <p style="text-align: justify;"><b>FOR MORE INFORMATION, PLEASE CONTACT:</b></p>

    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 8%;"><font style="background-color: #ffffff;">Contact:</font></td>
            <td style="width: 50%;"><font style="background-color: #ffffff;">Ian B. Walters, MD, Chief Executive Officer</font></td>
        </tr>
        <tr>
            <td style="width: 8%;"><font style="background-color: #ffffff;">Tel.:</font></td>
            <td style="width: 50%;"><font style="background-color: #ffffff;">203.221.7378</font></td>
        </tr>
        <tr>
            <td style="width: 8%;"><font style="background-color: #ffffff;">Email:</font></td>
            <td style="width: 50%;"><font style="color: #0000ff; background-color: #ffffff;"><u>ian@portagebiotech.com</u> </font><font style="color: #222222; background-color: #ffffff;">or</font><font style="color: #222222; background-color: #ffffff;">&#160;</font></td>
        </tr>
        <tr>
            <td style="width: 8%;"><font style="background-color: #ffffff;">Website:</font></td>
            <td style="width: 50%;"><font style="color: #0000ff; background-color: #ffffff;"><u>www.portagebiotech.com</u></font></td>
        </tr>
    </table>

    <p style="text-align: justify;">&#160;</p>
    <div>
        <p style="text-align: center;">- 2 -</p>
    </div>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99-1x001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  0" P,# @0# P,$! 0$!0D&!04%
M!0L(" 8)#0L-#0T+# P.$!01#@\3#PP,$A@2$Q46%Q<7#A$9&QD6&A06%Q;_
MVP!# 00$! 4%!0H&!@H6#PP/%A86%A86%A86%A86%A86%A86%A86%A86%A86
M%A86%A86%A86%A86%A86%A86%A86%A;_P  1"  X (0# 2(  A$! Q$!_\0
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:$4;=-PC/RD\GJ#77444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
